| Dr Alice H Morgan, MD, PHD | |
|
833 Saint Vincents Dr, Pob# 3 Suite 402, Birmingham, AL 35205-1606 | |
| (205) 933-9236 | |
| (205) 933-9213 |
| Full Name | Dr Alice H Morgan |
|---|---|
| Gender | Female |
| Speciality | Otolaryngology |
| Experience | 42 Years |
| Location | 833 Saint Vincents Dr, Birmingham, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861401192 | NPI | - | NPPES |
| 000032323 | Medicaid | AL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 10924 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cullman Regional Medical Center | Cullman, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ent Associates Of Alabama, P.c. | 8921025354 | 34 |
News Archive
An interesting new study by researchers at the University of Liverpool, University of Bristol and Public Health England in the UK describes a novel bioinformatics tool used to detect subgenomic messenger ribonucleic acid (mRNA) sequences from the virus. This may help develop new diagnostic tools and model the transmission of the virus.
Seven innovative research projects tackling pancreatic cancer have been awarded grants totalling £1.2M by the UK medical research charity, Pancreatic Cancer Research Fund.
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, presented results of a Phase I open-label dose-escalation study with Debio 0932, an oral Heat Shock Protein 90 (HSP90) inhibitor in clinical development as an anti-cancer agent.
News outlets cover health care developments in California, Georgia, Iowa, Kansas, Maine, Missouri and New York.
› Verified 1 days ago
| Entity Name | Ent Associates Of Alabama, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841301082 PECOS PAC ID: 8921025354 Enrollment ID: O20051025001005 |
News Archive
An interesting new study by researchers at the University of Liverpool, University of Bristol and Public Health England in the UK describes a novel bioinformatics tool used to detect subgenomic messenger ribonucleic acid (mRNA) sequences from the virus. This may help develop new diagnostic tools and model the transmission of the virus.
Seven innovative research projects tackling pancreatic cancer have been awarded grants totalling £1.2M by the UK medical research charity, Pancreatic Cancer Research Fund.
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, presented results of a Phase I open-label dose-escalation study with Debio 0932, an oral Heat Shock Protein 90 (HSP90) inhibitor in clinical development as an anti-cancer agent.
News outlets cover health care developments in California, Georgia, Iowa, Kansas, Maine, Missouri and New York.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Alice H Morgan, MD, PHD 833 Saint Vincents Dr, Pob# 3 Suite 402, Birmingham, AL 35205-1606 Ph: (205) 933-9236 | Dr Alice H Morgan, MD, PHD 833 Saint Vincents Dr, Pob# 3 Suite 402, Birmingham, AL 35205-1606 Ph: (205) 933-9236 |
News Archive
An interesting new study by researchers at the University of Liverpool, University of Bristol and Public Health England in the UK describes a novel bioinformatics tool used to detect subgenomic messenger ribonucleic acid (mRNA) sequences from the virus. This may help develop new diagnostic tools and model the transmission of the virus.
Seven innovative research projects tackling pancreatic cancer have been awarded grants totalling £1.2M by the UK medical research charity, Pancreatic Cancer Research Fund.
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, presented results of a Phase I open-label dose-escalation study with Debio 0932, an oral Heat Shock Protein 90 (HSP90) inhibitor in clinical development as an anti-cancer agent.
News outlets cover health care developments in California, Georgia, Iowa, Kansas, Maine, Missouri and New York.
› Verified 1 days ago
Dr. Grayson K Rodgers, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2700 10th Ave S Ste 502, Birmingham, AL 35205 Phone: 205-933-2951 Fax: 205-933-5893 | |
Dr. Jessica Warren Grayson, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 619 19th St S, Birmingham, AL 35249 Phone: 205-934-4011 | |
Brian Kulbersh, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 1940 Elmer J Bissell Rd, Birmingham, AL 35243 Phone: 205-638-4949 Fax: 205-638-4982 | |
Dr. Richard Kailean Mchugh, MD, PHD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2000 6th Ave S, The Kirklin Clinic, Birmingham, AL 35233 Phone: 205-801-8000 | |
Paul F Castellanos, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 619 19th Street South, Birmingham, AL 35233 Phone: 205-934-6600 | |
Dr. David Michael Walters, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1809 Gadsden Hwy, Birmingham, AL 35235 Phone: 205-838-3755 Fax: 205-838-3755 | |
Do Yeon Cho, Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2000 6th Ave S, Birmingham, AL 35233 Phone: 205-934-9999 |